Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma Limited has appointed Dr. Andrew Y. Sun, a renowned urologist and expert in male sexual health, to its Scientific Advisory Board to support the U.S. launch of its intranasal therapies, ROXUS® and SPONTAN®. This strategic move is aimed at capturing a share of the $3.7 billion erectile dysfunction market by offering alternatives for patients intolerant to oral PDE5 inhibitors. Dr. Sun’s extensive experience and influence in the field are expected to enhance prescriber adoption and position LTR Pharma’s products as preferred options, ahead of the planned commercial launch in the first half of 2026.
More about LTR Pharma Limited
LTR Pharma is an emerging pharmaceutical company focused on developing and commercializing innovative therapies to address significant unmet medical needs. The company utilizes a proprietary intranasal drug delivery platform to provide rapid, non-invasive treatment options across various therapeutic areas. Its leading products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for erectile dysfunction, and it is also developing OROFLOW® for Oesophageal Motility Disorders.
Average Trading Volume: 511,577
Technical Sentiment Signal: Sell
See more data about LTP stock on TipRanks’ Stock Analysis page.